
    
      The study duration for an individual patient will include a screening period for inclusion of
      up to 21 days, the treatment period consisting of 28 day cycles and a follow-up period.
      Treatment with isatuximab may continue until disease progression, unacceptable adverse event
      or other reason for discontinuation.
    
  